Akela Pharma restarts inhalation toxicology studies

Dr. Halvor Jaeger reports AKELA PHARMA REPEATS ITS FENTANYL TAIFUN(R) PRECLINICAL TOXICOLOGY STUDIES Akela Pharma Inc., as previously requested by the Food and Drug Administration, has started over again the required inhalation toxicology studies. The studies performed at CRO based in the United States are expected to produce results allowing Akela to start the longer-term safety arm of the Fentanyl Taifun phase III clinical trial in patients in the second quarter... [read full story]